ArticleFrontiers in cell and developmental biology2026
A metabolic-inflammatory burden phenotype associated with urinary glucose in colorectal cancer.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysregulation and chronic inflammation are frequently observed in individuals with colorectal cancer (CRC), particularly in the context of diabetes-related conditions. Identifying simple clinical indicators that reflect these combined alterations remains of interest. Urinary glucose, routinely assessed in clinical practice, may capture transient metabolic stress, but its association with integrated metabolic-inflammatory characteristics in CRC has not been systematically evaluated. Methods: A hospital-based cross-sectional case-control analysis was conducted, including individuals with confirmed colorectal cancer (CRC) and non-CRC controls undergoing clinical evaluation during the same period. A composite Metabolic-Inflammatory Burden Score (MIBS) was constructed using urinary glucose status together with selected inflammatory and tumor markers. Multivariable logistic regression was performed with CRC status (1 = CRC, 0 = non-CRC) as the dependent variable, and model performance was assessed in the primary cohort. External validation was performed in an independent NHANES subset using a reduced model consistent with the variables available in that dataset. Results: Individuals with higher urinary glucose categories exhibited higher levels of systemic inflammation and tumor-related markers, along with altered immune cell profiles. Urinary glucose remained associated with CRC after adjustment for demographic, metabolic, inflammatory, and molecular factors. Incorporation of urinary glucose into the composite framework was associated with improved model discrimination in the primary analysis, and similar patterns were observed in the external NHANES cohort, including differences in predicted risk distributions across urinary glucose categories. Conclusion: Urinary glucose was associated with distinct metabolic-inflammatory characteristics in CRC and contributed to a composite burden framework that demonstrated consistent patterns in an independent population-based dataset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.